References
- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
- Kim JM, Shin DJ, Bae YJ, et al. Association between I/D, G14480C, A22982G polymorphisms of angiotension I-converting enzyme gene and essential hypertension in the Korean population. Korean Circ J 2004;34:1137-47
- Lee JA, Sohn JA, Hong YM. Polymorphism of angiotensin II type 1 receptor A1166C in Korean hypertensive adolescents. Korean Circ J 2008;38:405-10 https://doi.org/10.4070/kcj.2008.38.8.405
- Jalil JE, Doering CW, Janicki JS, Pick RZ, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989;64:1041-50
- Bashey RI, Cox R, McCann J, Jimenez SA. Changes in collagen biosynthesis, types, and mechanics of aorta in hypertensive rats. J Lab Clin Med 1989;113:604-11
- Laviades C, Vain N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535-40
- Safar ME. Therapeutic trials and large arteries in hypertension. Am Heart J 1988;115:702-10 https://doi.org/10.1016/0002-8703(88)90830-7
- Dzau VJ, Safar ME. Large conduit arteries in hypertension: role of the renin-angiotensin system. Circulation 1988;77:947-54 https://doi.org/10.1161/01.CIR.77.5.947
- Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-96 https://doi.org/10.1161/CIRCULATIONAHA.105.573865
- Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer:innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72 https://doi.org/10.1038/nrc884
- Parks WE. A confederancy of proteinases. J Clin Invest 2002;110:613-4 https://doi.org/10.1172/JCI0216550
- Vu TH, Werbz Z. Matrix metalloprotienases: effectors of development and normal physiology. Genes Dev 2000;14:2123-33 https://doi.org/10.1101/gad.815400
- Karthikeyan VJ, Lip GY. Matrix metalloproteinases and hypertension: a link between left ventricular hypertrophy and diastolic function? Tohoku J Exp Med 2006:208:93-7 https://doi.org/10.1620/tjem.208.93
- Saglam M, Karakaya O, Esen AM, et al. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku J Exp Med 2006;208:117-22 https://doi.org/10.1620/tjem.208.117
- Tayebjee MH, Nedar SK, MacFadyen RJ, Lip GY. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension: relationship to tissue Doppler indicies of diastolic relaxation. Am J Hypertens 2004;17:770-4
- Tayebjee MH, Lim HS, Nadar S, MacFadyen RJ, Lip GY. Tissue inhibitor of metalloproteinases-I is a marker of diastolic dysfunction using tissue Doppler in patients with type 2 diabetes and hypertension. Eur J Clin Invest 2005;35:8-12 https://doi.org/10.1111/j.1365-2362.2005.01438.x
- Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003;17:119-24 https://doi.org/10.1038/sj.jhh.1001518
- Asano Y, Iwai S, Okazaki M, et al. Matrix metalloproteinase-9 in spontaneously hypertensive hyperlipidemic rats. Pathophysiology 2008;15:157-66 https://doi.org/10.1016/j.pathophys.2007.02.001
- Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372
- Murphy G, Ward R, Gavrilovic J, Atkinson S. Physiological mechanisms for metalloproteinase activation. Matrix Suppl 1992;1:224-30
- Seccia TM, Bettini E, Vukous V, et al. Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats. Blood Press 1999;8:57-64 https://doi.org/10.1080/080370599438400
- Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 2004;24:1479-84 https://doi.org/10.1161/01.ATV.0000135656.49158.95
- Rhee MY, Lee HY, Park JB. Measurements of arterial stiffness:methological aspects. Korean Circ J 2008;38:343-50 https://doi.org/10.4070/kcj.2008.38.7.343
- Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res 2007;30:959-63 https://doi.org/10.1291/hypres.30.959
- Lin J, Davis HB, Dai Q, et al. Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res 2008;31:1225-31 https://doi.org/10.1291/hypres.31.1225
- Ishikawa J, Kario K, Matsui Y, et al. Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy. Hypertens Res 2005;28:995-1001 https://doi.org/10.1291/hypres.28.995
- Armstrong C, Abilleira S, Sitzer M, Markus H, Bevan S. Polymorphsims in MMP family and TIMP genes and carotid artery intima-media thickness. Stroke 2007;38:2895-9 https://doi.org/10.1161/STROKEAHA.107.491696